Skip to main content
. 2019 Dec 8;182(6):1369–1378. doi: 10.1111/bjd.18552

Table 1.

Efficacy outcomes per central review at 42 months

laBCC mBCC
200 mg (n = 66) 800 mg (n = 128) 200 mg (n = 13) 800 mg (n = 23)
ORR, % (95% CI) 56 (43–68) 46·1 (37·2–55·1) 8 (0·2–36) 17 (5–39)
CR, % (95%, CI) 5 (0·9–13) 1·6 (0·2–5·5) 0 (0–25) 0 (0–15)
DCR, % 91 82·0 92 91
DOR, median, months (95% CI) 26·1 (NE) 23·3 (12·2–29·6) 24·0 (NE) NE (NE)
PFS, median, months (95% CI) 22·1 (NE) 24·9 (19·2–33·4) 13·1 (5·6–33·1) 11·1 (7·3–16·6)
TTR, median, months (95% CI) 4·0 (3·8–5·6) 3·8 (3·7–5·5) 9·2 (NE) 1·0 (1·0–2·1)

The results are for the intent‐to‐treat population. BCC, basal cell carcinoma; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; laBCC, locally advanced BCC; mBCC, metastatic BCC; NE, not estimable; ORR, objective response rate; PFS, progression‐free survival; TTR, time to tumour response.